User:Mr. Ibrahem/Ceritinib

Mr. Ibrahem/Ceritinib
Clinical data
Pronunciation	Ceritinib: /səˈrɪtɪnɪb/ sə-RIT-i-nib; Zykadia: /zaɪˈkeɪdiːə/ zy-KAY-dee-ə
Trade names	Zykadia, Spexib, others
Other names	LDK378
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN;
Routes of; administration	By mouth (capsules)
Drug class	ALK inhibitor
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	Not determined
Protein binding	97%
Metabolism	CYP3A
Elimination half-life	41 hours
Excretion	Feces (92.3%), urine (1.3%)
Identifiers
	IUPAC name 5-Chloro-N2-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine;
Chemical and physical data
Formula	C28H36ClN5O3S
Molar mass	558.14 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl;
	InChI InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34); Key:VERWOWGGCGHDQE-UHFFFAOYSA-N;

Ceritinib, sold under the brand name Zykadia among others, is a medication used to treat non-small cell lung cancer (NSCLC).^[1] Specifically it is used for advanced disease that is anaplastic lymphoma kinase (ALK) positive.^[1] It is taken by mouth.^[3]

Common side effects include diarrhea, nausea, tiredness, liver problems, weight loss, rash, kidney problems, and low red blood cells.^[1] Other side effects may include high blood sugar, pneumonitis, QT prolongation, and pancreatitis.^[1]^[3] Use in pregnancy may harm the baby.^[3] It is a tyrosine kinase inhibitor, specifically a ALK inhibitor.^[1]^[4]

Ceritinib was approved for medical use in the United States in 2014 and Europe in 2015.^[1] In the United Kingdom 4 weeks of treatment costs the NHS about £2,800 as of 2021.^[4] This amount in the United States is about 10,400 USD.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Zykadia". Archived from the original on 13 October 2021. Retrieved 3 January 2022.
^ "Zykadia (ceritinib) Capsules, for Oral Use. Full Prescribing Information" (PDF). Novartis Pharmaceuticals Corporation. Archived (PDF) from the original on 28 April 2019. Retrieved 14 February 2017.
^ ^a ^b ^c "DailyMed - ZYKADIA- ceritinib tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 24 March 2021. Retrieved 3 January 2022.
^ ^a ^b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1018. ISBN 978-0857114105.
^ "Ceritinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 3 January 2022.

[EPAR2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Zykadia". Archived from the original on 13 October 2021. Retrieved 3 January 2022.

[PI-2] "Zykadia (ceritinib) Capsules, for Oral Use. Full Prescribing Information" (PDF). Novartis Pharmaceuticals Corporation. Archived (PDF) from the original on 28 April 2019. Retrieved 14 February 2017.

[PI2022-3] "DailyMed - ZYKADIA- ceritinib tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 24 March 2021. Retrieved 3 January 2022.

[BNF81-4] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1018. ISBN 978-0857114105.

[5] "Ceritinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 3 January 2022.

[1]

[2]

[3]

[4]

[5]